TR199802238T2 - Astımın TNFR-Ig ile tedavisi. - Google Patents
Astımın TNFR-Ig ile tedavisi.Info
- Publication number
- TR199802238T2 TR199802238T2 TR1998/02238T TR9802238T TR199802238T2 TR 199802238 T2 TR199802238 T2 TR 199802238T2 TR 1998/02238 T TR1998/02238 T TR 1998/02238T TR 9802238 T TR9802238 T TR 9802238T TR 199802238 T2 TR199802238 T2 TR 199802238T2
- Authority
- TR
- Turkey
- Prior art keywords
- asthma
- treatment
- tnfalfa
- symmetrical
- binding protein
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title abstract 3
- 102000014914 Carrier Proteins Human genes 0.000 abstract 2
- 108091008324 binding proteins Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1684296P | 1996-05-08 | 1996-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR199802238T2 true TR199802238T2 (xx) | 1999-02-22 |
Family
ID=21779275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR1998/02238T TR199802238T2 (xx) | 1996-05-08 | 1997-05-02 | Astımın TNFR-Ig ile tedavisi. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0910413A2 (fr) |
| JP (1) | JP2000510113A (fr) |
| KR (1) | KR20000010825A (fr) |
| CN (1) | CN1233189A (fr) |
| AR (1) | AR007020A1 (fr) |
| AU (1) | AU725408B2 (fr) |
| BR (1) | BR9708928A (fr) |
| CA (1) | CA2253557A1 (fr) |
| CO (1) | CO4820397A1 (fr) |
| HR (1) | HRP970224A2 (fr) |
| MA (1) | MA24169A1 (fr) |
| PE (1) | PE70698A1 (fr) |
| TR (1) | TR199802238T2 (fr) |
| WO (1) | WO1997041895A2 (fr) |
| ZA (1) | ZA973843B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL136988A0 (en) * | 1997-12-29 | 2001-06-14 | Regeneron Pharma | Novel nucleic acid and polypeptide |
| TR200504220T2 (tr) | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US20010021380A1 (en) * | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| JP4980048B2 (ja) * | 2003-02-28 | 2012-07-18 | アレス トレーディング ソシエテ アノニム | 腫瘍壊死因子結合タンパク質の液体製剤 |
| US7335491B2 (en) * | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
| CN101600450A (zh) | 2006-10-20 | 2009-12-09 | 比奥根艾迪克Ma公司 | 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗 |
| US8338376B2 (en) | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
| EP3488851A1 (fr) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Thérapies immunoablatives |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0939121B2 (fr) * | 1989-09-12 | 2007-12-26 | AHP Manufacturing B.V. | Protéines liant le TNF |
| AU670125B2 (en) * | 1992-09-15 | 1996-07-04 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
| US5684222A (en) * | 1993-01-22 | 1997-11-04 | Ontario Cancer Institute | Mutant mouse having a disrupted TNFRp55 |
| CA2119089A1 (fr) * | 1993-03-29 | 1994-09-30 | David Banner | Muteines du facteur de necrose tumoral |
| AU3111995A (en) * | 1994-07-22 | 1996-02-22 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions comprising a chimaeric tnf binding protein |
| US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| IL116436A (en) * | 1995-12-18 | 2006-12-31 | Yissum Res Dev Co | Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND |
-
1997
- 1997-05-02 EP EP97921849A patent/EP0910413A2/fr not_active Withdrawn
- 1997-05-02 HR HR60/016,842A patent/HRP970224A2/xx not_active Application Discontinuation
- 1997-05-02 AU AU27764/97A patent/AU725408B2/en not_active Ceased
- 1997-05-02 CA CA002253557A patent/CA2253557A1/fr not_active Abandoned
- 1997-05-02 KR KR1019980708961A patent/KR20000010825A/ko not_active Withdrawn
- 1997-05-02 JP JP09539522A patent/JP2000510113A/ja active Pending
- 1997-05-02 CN CN97194455A patent/CN1233189A/zh active Pending
- 1997-05-02 TR TR1998/02238T patent/TR199802238T2/xx unknown
- 1997-05-02 MA MA24590A patent/MA24169A1/fr unknown
- 1997-05-02 WO PCT/EP1997/002256 patent/WO1997041895A2/fr not_active Ceased
- 1997-05-02 BR BR9708928-1A patent/BR9708928A/pt not_active Application Discontinuation
- 1997-05-05 PE PE1997000351A patent/PE70698A1/es not_active Application Discontinuation
- 1997-05-05 ZA ZA9703843A patent/ZA973843B/xx unknown
- 1997-05-06 AR ARP970101876A patent/AR007020A1/es not_active Application Discontinuation
- 1997-05-07 CO CO97024335A patent/CO4820397A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2253557A1 (fr) | 1997-11-13 |
| MA24169A1 (fr) | 1997-12-31 |
| WO1997041895A2 (fr) | 1997-11-13 |
| ZA973843B (en) | 1997-11-10 |
| BR9708928A (pt) | 2000-05-09 |
| PE70698A1 (es) | 1998-11-18 |
| CN1233189A (zh) | 1999-10-27 |
| AU2776497A (en) | 1997-11-26 |
| KR20000010825A (ko) | 2000-02-25 |
| JP2000510113A (ja) | 2000-08-08 |
| AU725408B2 (en) | 2000-10-12 |
| EP0910413A2 (fr) | 1999-04-28 |
| WO1997041895A3 (fr) | 1998-03-12 |
| HRP970224A2 (en) | 1998-04-30 |
| AR007020A1 (es) | 1999-10-13 |
| CO4820397A1 (es) | 1999-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998018826A3 (fr) | Anticorps anti-ccr5 et procedes d'utilisation correspondants | |
| ES2293973T3 (es) | Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos. | |
| EP1958965A3 (fr) | Anticorps agonistes pour un récepteur musk, et leurs utilisations thérapeutiques | |
| EP0536275A4 (en) | Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof | |
| BG109311A (en) | PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNFAL, AND HIS APPLICATION | |
| EP0528931A4 (en) | Humanized chimeric anti-icam-1 antibodies, methods of preparation and use | |
| TR199800091T1 (xx) | Ba����kl�k hastal�klar�n�n tedavisi i�in terap�tik maddeler olarak kullan�lan ��z�nebilir lenfotoksin-� resept�rleri ve anti-lenfotoksin resept�r� ve ligand� antikorlar�. | |
| EP0837927A4 (fr) | Anticorps monoclonaux simiens diriges specifiquement contre le b7.1 et/ou b7.2 humains, leurs formes adaptees aux primates, et compositions pharmaceutiques | |
| DE69941598D1 (de) | Anti-ccr2 antikörper sowie deren verwendung | |
| DE69622074D1 (de) | Cystin-Silikon-Copolymere und deren Verwendung zur Behandlung von keratinischen Materialien | |
| DE69737592D1 (de) | Mittel gegen juckreiz | |
| DE69637781D1 (de) | Für den il-13 rezeptor spezifische chimäre proteine und ihre verwendungen | |
| BR9510486A (pt) | Compostos moduladores de receptores de esteróide e métodos | |
| MY145191A (en) | Human antibodies that bind human il-12 and methods for producing | |
| BR0114646A (pt) | anticorpos anti-lt-beta-r humanizados | |
| BR9106392A (pt) | Anticorpos anti-icam-1 enxertados-cdr humanizados,metodos de preparacao e uso dos mesmos | |
| AU3376297A (en) | Human thyrotropin receptor compositions and use thereof | |
| NZ329807A (en) | NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome | |
| TR199802238T2 (xx) | Astımın TNFR-Ig ile tedavisi. | |
| DE69837387D1 (de) | (d)-METHADON, EIN NICHT-OPIOIDES SCHMERZMITTEL | |
| PT954333E (pt) | Receptores soluveis de linfotoxina-beta, anticorpos de receptores de anti-linfotoxina e anticorpos de ligandos de anti-linfotoxina como agentes terapeuticos para o tratamento de doencas imunologicas | |
| AU1667500A (en) | N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists | |
| TR200001288T2 (tr) | Östrojen yoksunluğu sendromunun tedavisinde faydalı 2-arilbenzo (b) tiyofenler. | |
| ES2140489T3 (es) | Receptor de interferona soluble, su preparacion y su uso. | |
| PT939809E (pt) | Ligandos do receptor de tie-2 (ligando 3 de tie e ligando 4 de tie) e suas utilizacoes |